<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04203862</url>
  </required_header>
  <id_info>
    <org_study_id>NPC-22</org_study_id>
    <nct_id>NCT04203862</nct_id>
  </id_info>
  <brief_title>A Study of NPC-22 in Healthy Adult Males</brief_title>
  <official_title>A Phase 1 Single Ascending Dose Study of NPC-22 in Healthy Adult Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nobelpharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nobelpharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to examine the safety and pharmacokinetics of NPC-22
      administered in a single ascending dose in healthy adult males.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The healthy adult males will be randomized into six arms, and will receive single dose of
      NPC-22 (five doses, placebo)
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 19, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 29, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>0-7 days post dose</time_frame>
    <description>An adverse event will refer to any unfavorable or unintended sign (including an abnormal laboratory finding and abnormality on the 12-lead ECG or in vital signs) and symptom</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body temperature</measure>
    <time_frame>0-7 days post dose</time_frame>
    <description>Body temperature will be measured for assess the safety of single ascending dose of NPC-22</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>0-7 days post dose</time_frame>
    <description>Blood pressure will be measured for assess the safety of single ascending dose of NPC-22</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulse rate</measure>
    <time_frame>0-7 days post dose</time_frame>
    <description>Pulse rate will be measured for assess the safety of single ascending dose of NPC-22</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG</measure>
    <time_frame>0-7 days post dose</time_frame>
    <description>RR, PR, QRS, QT and QTcF interval and heart rate will be measured for assess the safety of single ascending dose of NPC-22</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and/or rates of subjects with treatment-related adverse events as assessed by hematology tests</measure>
    <time_frame>0-7 days post dose</time_frame>
    <description>Hematology tests will be performed for assessment the safety of single ascending dose of NPC-22</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and/or rates of subjects with treatment-related adverse events as assessed by blood chemistry tests</measure>
    <time_frame>0-7 days post dose</time_frame>
    <description>Blood chemistry tests will be performed for assessment the safety of single ascending dose of NPC-22</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and/or rates of subjects with treatment-related adverse events as assessed by urinalysis</measure>
    <time_frame>0-7 days post dose</time_frame>
    <description>Urinalysis will be performed for assessment the safety of single ascending dose of NPC-22</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Observed plasma concentration</measure>
    <time_frame>0-7 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed urine concentration</measure>
    <time_frame>0-4 days post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy Adult Subjects</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of low dose NPC-22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of low/middle dose NPC-22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of middle dose NPC-22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of middle/high dose NPC-22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of high dose NPC-22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of placebo dose NPC-22</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPC-22</intervention_name>
    <description>Single administration of low dose NPC-22</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPC-22</intervention_name>
    <description>Single administration of low/middle dose NPC-22</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPC-22</intervention_name>
    <description>Single administration of middle dose NPC-22</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPC-22</intervention_name>
    <description>Single administration of middle/high dose NPC-22</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPC-22</intervention_name>
    <description>Single administration of high dose NPC-22</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPC-22 Placebo</intervention_name>
    <description>Single administration of NPC-22 Placebo</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who have provided their own written informed consent

          2. Subjects aged ≥20 and &lt;40 years at the time of informed consent

          3. Subjects with body weight of ≥50 kg and body mass index (BMI) (kg/m2) of ≥18.5 and
             &lt;25.0

          4. Subjects who were identified to have no health problem on physical examination,
             physical assessment, laboratory tests, or other examinations at screening by the
             principal investigator or a sub-investigator

        Exclusion Criteria:

          1. Subjects with a complication or a history of drug abuse (use of an illicit drug) or
             alcohol dependence

          2. Subjects with a history of severe disease that may recur during the study period

          3. Subjects with any concurrent illnesses

          4. Subjects who received another study drug within 180 days prior to the start of study
             drug administration

          5. Subjects who donated blood of ≥400 mL within 12 weeks, blood of ≥200 mL within 4
             weeks, or blood components within 2 weeks prior to the start of the study

          6. Subjects who used any medicinal product (including over the counter drugs except for
             topical products) or similar product like a dietary supplement (including health food)
             within 7 days prior to the start of study drug administration

          7. Subjects who took any food or beverage containing grapefruit or St. John's wort within
             7 days prior to the start of study drug administration

          8. Subjects who took any alcohol or caffeine-containing beverage within 3 days prior to
             the start of study drug administration

          9. Subjects who smoked within 90 days prior to the start of study drug administration, or
             do not agree to stop smoking during the study period

         10. Subjects who had a positive result for HBs antigen, HCV antibody, or HIV
             antigen/antibody, or a positive reaction to syphilis serology or urine drug test at
             screening

         11. Subjects who are unsuitable as a subject in this study in the judgement of the
             principal investigator or a sub-investigator based on the 12-lead electrocardiogram at
             screening [e.g., Fridericia's corrected QT (QTcF) interval of ≥450 ms]

         12. Subjects who have a familial history of torsades de pointes or long QT syndrome

         13. Subjects who are unsuitable as a subject in this study in the judgement of the
             principal investigator or a sub-investigator by having a deviation from the
             institutional reference values

         14. Subjects who are unsuitable as a subject in this study in the judgement of the
             principal investigator or a sub-investigator due to other reasons
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical Corporation Shinanokai Shinanozaka Clinic</name>
      <address>
        <city>Shinjuku</city>
        <state>Tokyo</state>
        <zip>160-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 17, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2019</study_first_posted>
  <last_update_submitted>January 20, 2020</last_update_submitted>
  <last_update_submitted_qc>January 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

